PD-1/PD-L1 inhibitors plus chemotherapy as first-line therapy for advanced or metastatic endometrial cancer: a systematic review and meta-analysis of randomized controlled trials - Top-Institutions - MDSpire

PD-1/PD-L1 inhibitors plus chemotherapy as first-line therapy for advanced or metastatic endometrial cancer: a systematic review and meta-analysis of randomized controlled trials

  • By

  • Zhilong Huang

  • Wenwen Li

  • Minghong Li

  • Yifu Huang

  • Yongjiang Lu

  • Jiahang Hu

  • June 1, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Gynecologic Oncology
    • Medical Oncology

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Gynecologic Medical Oncology
    • Medical Oncology

  • #3

    Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute
    Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute

    Boston, Massachusetts

    Key Differentiators

    • Gynecologic Oncology
    • Medical Oncology

Original Source(s)

PD-1/PD-L1 inhibitors plus chemotherapy as first-line therapy for advanced or metastatic endometrial cancer: a systematic review and meta-analysis of randomized controlled trials

  • by Zhilong Huang, Wenwen Li, Minghong Li, Yifu Huang, Yongjiang Lu, Jiahang Hu

  • June 1, 2026

Related Content

Case Report: Tumor regression and neurological recovery in paraplegia from POLD1-mutated hepatocellular carcinoma treated with targeted immunotherapy and electroacupuncture

Treatment of parotid gland oncocytoma: a case report from a radiation oncologist’s perspective

Engineered virus-hunter vaccine overcomes HBV immune tolerance